These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 19855172)

  • 1. Evaluation of p63 and p73 antibodies for cross-reactivity.
    Rosenbluth JM; Johnson K; Tang L; Triplett T; Pietenpol JA
    Cell Cycle; 2009 Nov; 8(22):3702-6. PubMed ID: 19855172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies raised against Xenopus p53 interact with human p73.
    Le Bras M; Delattre V; Bensaad K; Blandino G; Soussi T
    Oncogene; 2002 Feb; 21(8):1304-8. PubMed ID: 11850851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.
    Nekulova M; Holcakova J; Nenutil R; Stratmann R; Bouchalova P; Müller P; Mouková L; Coates PJ; Vojtesek B
    Virchows Arch; 2013 Sep; 463(3):415-25. PubMed ID: 23887585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress.
    Murray-Zmijewski F; Lane DP; Bourdon JC
    Cell Death Differ; 2006 Jun; 13(6):962-72. PubMed ID: 16601753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p63 and p73: roles in development and tumor formation.
    Moll UM; Slade N
    Mol Cancer Res; 2004 Jul; 2(7):371-86. PubMed ID: 15280445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of p73 antibodies in patients with various types of cancer: immunological characterization.
    Tominaga O; Unsal K; Zalcman G; Soussi T
    Br J Cancer; 2001 Jan; 84(1):57-63. PubMed ID: 11139314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue.
    Lo Iacono M; Monica V; Saviozzi S; Ceppi P; Bracco E; Papotti M; Scagliotti GV
    J Thorac Oncol; 2011 Mar; 6(3):473-81. PubMed ID: 21289519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.
    Gaiddon C; Lokshin M; Ahn J; Zhang T; Prives C
    Mol Cell Biol; 2001 Mar; 21(5):1874-87. PubMed ID: 11238924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance.
    Hong SM; Cho H; Moskaluk CA; Yu E; Zaika AI
    J Mol Histol; 2007 Jun; 38(3):167-75. PubMed ID: 17385050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73.
    Stiewe T; Stanelle J; Theseling CC; Pollmeier B; Beitzinger M; Pützer BM
    J Biol Chem; 2003 Apr; 278(16):14230-6. PubMed ID: 12584188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget's disease.
    Chen S; Moroi Y; Urabe K; Takeuchi S; Kido M; Hayashida S; Uchi H; Uenotsuchi T; Tu Y; Furue M
    Clin Exp Dermatol; 2008 Aug; 33(5):634-40. PubMed ID: 18627398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One, two, three--p53, p63, p73 and chemosensitivity.
    Müller M; Schleithoff ES; Stremmel W; Melino G; Krammer PH; Schilling T
    Drug Resist Updat; 2006 Dec; 9(6):288-306. PubMed ID: 17287142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer.
    Tannapfel A; Schmelzer S; Benicke M; Klimpfinger M; Kohlhaw K; Mössner J; Engeland K; Wittekind C
    J Pathol; 2001 Sep; 195(2):163-70. PubMed ID: 11592094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of the expression of p53, p63 and p73 in nasal and paranasal sinus carcinoma].
    Zhang T; Jia H; Wang J; Shan Y; Luo S; Tang Z
    Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Oct; 22(20):919-21. PubMed ID: 19119599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p63 and p73 in retinoblastoma: a clinicopathological correlation study.
    Adithi M; Nalini V; Kandalam M; Krishnakumar S
    Exp Eye Res; 2008 Oct; 87(4):312-8. PubMed ID: 18619959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53.
    Davison TS; Vagner C; Kaghad M; Ayed A; Caput D; Arrowsmith CH
    J Biol Chem; 1999 Jun; 274(26):18709-14. PubMed ID: 10373484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Int J Cancer; 2002 May; 99(1):22-8. PubMed ID: 11948487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network.
    Boominathan L
    Cancer Metastasis Rev; 2010 Dec; 29(4):613-39. PubMed ID: 20922462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.